Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982521priorityCriticalpatent/ECSP982521A/en
Publication of ECSP982521ApublicationCriticalpatent/ECSP982521A/en
La invención se refiere a la nueva modificación A, o bien A¿del compuesto 1-2(2,6-difluorbencial)-1H-1,2,3, triazol-4-carboxamida de la fórmula (gráfico), su empleo, así como preparados farmacéuticos que contienen esta modificación a cristal.The invention relates to the new modification A, or A¿ of compound 1-2 (2,6-difluorobenz) -1H-1,2,3, triazol-4-carboxamide of the formula (graph), its use, as well as pharmaceutical preparations containing this crystal modification.
ECSP9825211998-06-051998-06-05
CRYSTAL MODIFICATION OF AN ACTIVE MEDICINAL SUBSTANCE (I)
ECSP982521A
(en)
TRICYCLIC UREA COMPOUNDS USEFUL FOR THE INHIBITION OF THE FUNCTION OF PROTEIN G AND FOR THE TREATMENT OF PROTEOLYTIC DISEASES, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES.
DERIVATIVES OF BENCIMIDAZOL 1-ARIL-2-N, S OR O-SUBSTITUTES, ITS USE FOR THE OBTAINING OF PHARMACEUTICAL DRUGS AND PREPARATIONS CONTAINING THESE DERIVATIVES